Clovis Oncology Inc. (NASDAQ:CLVS) had its target price boosted by Stifel Nicolaus from $30.00 to $45.00 in a research note released on Wednesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Several other equities research analysts have also issued reports on CLVS. Vetr lowered shares of Clovis Oncology from a strong-buy rating to a buy rating and set a $17.66 price target on the stock. in a research note on Wednesday, May 25th. Credit Suisse Group AG reissued a hold rating on shares of Clovis Oncology in a research report on Wednesday, June 8th. Piper Jaffray Cos. reissued a hold rating and issued a $14.00 price objective on shares of Clovis Oncology in a research report on Wednesday, June 29th. SunTrust Banks Inc. initiated coverage on shares of Clovis Oncology in a research report on Friday, August 5th. They issued a buy rating and a $25.00 price objective for the company. Finally, JPMorgan Chase & Co. reissued a hold rating and issued a $13.00 price objective on shares of Clovis Oncology in a research report on Tuesday, August 9th. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $32.20.

Clovis Oncology (NASDAQ:CLVS) traded up 0.101% on Wednesday, reaching $35.716. 446,561 shares of the company traded hands. The firm’s market cap is $1.38 billion. Clovis Oncology has a 52-week low of $11.57 and a 52-week high of $109.18. The stock has a 50-day moving average price of $22.84 and a 200-day moving average price of $17.30.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.13) by $0.06. During the same quarter last year, the business earned ($2.10) earnings per share. Analysts anticipate that Clovis Oncology will post ($9.32) earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of the company. CIBC World Markets Inc. boosted its stake in shares of Clovis Oncology by 7.8% in the first quarter. CIBC World Markets Inc. now owns 11,680 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 850 shares during the period. ProShare Advisors LLC boosted its stake in shares of Clovis Oncology by 3.2% in the second quarter. ProShare Advisors LLC now owns 33,584 shares of the biopharmaceutical company’s stock valued at $461,000 after buying an additional 1,056 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in shares of Clovis Oncology by 8.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 22,819 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 1,693 shares during the period. Rice Hall James & Associates LLC boosted its stake in shares of Clovis Oncology by 1.8% in the second quarter. Rice Hall James & Associates LLC now owns 94,594 shares of the biopharmaceutical company’s stock valued at $1,298,000 after buying an additional 1,716 shares during the period. Finally, American International Group Inc. boosted its stake in shares of Clovis Oncology by 12.4% in the second quarter. American International Group Inc. now owns 18,297 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 2,016 shares during the period. Institutional investors and hedge funds own 98.46% of the company’s stock.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

5 Day Chart for NASDAQ:CLVS

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.